Armata Stock Analysis

ARMP -  USA Stock  

USD 4.24  0.04  0.95%

The recent decline in stock price could raise concerns from insiders as the firm it trading at a share price of 4.24 on 3,814 in volume. The company directors and management have failed to build on market volatilities in May. However, diversifying your overall positions with Armata Pharmaceuticals may protect your principal portfolio during upcoming market swings. The stock standard deviation of daily returns for 90 days investing horizon is currently 2.82. The current volatility is consistent with the ongoing market swings in May 2021 as well as with Armata Pharmaceuticals unsystematic, company-specific events.
Please continue to Trending Equities.

Search Stock Analysis 

 
Refresh
The Armata Pharmaceuticals stock analysis report makes it easy to digest most publicly released information about Armata Pharmaceuticals and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Armata stock analysis module also helps to analyze the Armata Pharmaceuticals price relationship with some important fundamental indicators such as market cap and management efficiency.

Armata Stock Analysis Notes

About 75.0% of the company shares are held by company insiders. The book value of Armata Pharmaceuticals was presently reported as 1.01. The company recorded a loss per share of 1.35. Armata Pharmaceuticals had not issued any dividends in recent years. The entity had a split on the 10th of May 2019. Armata Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for the treatment of antibiotic-resistant infections worldwide. It has a partnership agreement with Merck Co. for developing proprietary synthetic phage candidates to target undisclosed infectious disease agents. Armata Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NYSEMKT Exchange. It employs 59 people. For more info on Armata Pharmaceuticals please contact the company at 858 829 0829 or go to http://www.armatapharma.com.

Armata Pharmaceuticals Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Armata Pharmaceuticals' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Armata Pharmaceuticals or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Armata Pharmaceuticals generates negative expected return over the last 90 days
Armata Pharmaceuticals has a very high chance of going through financial distress in the upcoming years
The company reported the previous year's revenue of 823 K. Net Loss for the year was (22.18 M) with loss before overhead, payroll, taxes, and interest of (11.72 M).
Armata Pharmaceuticals currently holds about 9.65 M in cash with (18.27 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.39.
Armata Pharmaceuticals has a frail financial position based on the latest SEC disclosures
Roughly 75.0% of the company shares are held by company insiders
Latest headline from finance.yahoo.com: Where Do Hedge Funds Stand On Fang Holdings Limited - Yahoo Finance

Armata Pharmaceuticals Upcoming and Recent Events

Earnings reports are used by Armata Pharmaceuticals to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Armata Pharmaceuticals previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report12th of August 2021
Next Earnings Report11th of November 2021
Next Fiscal Quarter End30th of June 2021
Next Fiscal Year End17th of March 2022
Last Quarter Report31st of March 2021
Last Earning Announcement30th of June 2020

Armata Largest EPS Surprises

Earnings surprises can significantly impact Armata Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2021-05-13
2021-03-31-0.32-0.270.0515 
2020-11-12
2020-09-30-0.2475-0.31-0.062525 
2021-03-18
2020-12-31-0.2825-0.36-0.077527 
View All Earnings Estimates

Armata Pharmaceuticals SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Armata Pharmaceuticals prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Armata Pharmaceuticals investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Armata Pharmaceuticals specific information freely available to individual and institutional investors to make a timely investment decision.
14th of May 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
5th of April 2021
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Unclassified Corporate Event
View
17th of March 2021
Unclassified Corporate Event. Unclassified Corporate Event. Unclassified Corporate Event. Unclassified Corporate Event. Completion of Acquisition or Disposition of Assets
View
27th of January 2021
Financial Statements and Exhibits. Other Events. Unclassified Corporate Event. Unregistered Sales of Equity Securities. Entry into a Material Definitive Agreement
View
6th of January 2021
Financial Statements and Exhibits. Regulation FD Disclosure
View
9th of December 2020
Financial Statements and Exhibits. Other Events. Submission of Matters to a Vote of Security Holders
View

Armata Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Armata Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Armata Pharmaceuticals backward and forwards among themselves. Armata Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Armata Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Bank Of America CorpCommon Shares633.9 KM
Loomis Sayles Co L PCommon Shares130 K621 K
Renaissance Technologies LlcCommon Shares123.8 K592 K
Vanguard Group IncCommon Shares75.6 K362 K
Edgewood Management LlcCommon Shares50 K239 K
Bridgeway Capital Management LlcCommon Shares48.4 K231 K
Blackrock IncCommon Shares40.4 K194 K
Note, although Armata Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Armata Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 110.24 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Armata Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Armata Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Armata Profitablity

Armata Pharmaceuticals' profitability indicators refer to fundamental financial ratios that showcase Armata Pharmaceuticals' ability to generate income relative to its revenue or operating costs. If, let's say, Armata Pharmaceuticals is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Armata Pharmaceuticals' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Armata Pharmaceuticals' profitability requires more research than a typical breakdown of Armata Pharmaceuticals' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2021
Return on Average Assets(0.50) (0.53) 
Return on Average Equity(0.83) (0.85) 
Return on Invested Capital(0.81) (0.87) 
Return on Sales(30.12) (32.49) 

Management Efficiency

The entity has return on total asset (ROA) of (41.53) % which means that it has lost $41.53 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (132.62) %, meaning that it created substantial loss on money invested by shareholders. Armata Pharmaceuticals management efficiency ratios could be used to measure how well armata pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of 17th of June 2021, Return on Average Assets is likely to drop to -0.53. In addition to that, Return on Average Equity is likely to drop to -0.85. As of 17th of June 2021, Total Liabilities is likely to drop to about 17.5 M. In addition to that, Current Liabilities is likely to drop to about 5.5 M
Last ReportedProjected for 2021
Book Value per Share 1.15  1.18 
Enterprise Value over EBIT(2.00) (2.16) 
Enterprise Value over EBITDA(2.53) (2.73) 
Price to Book Value 2.96  2.78 
Tangible Assets Book Value per Share 2.19  2.26 
Enterprise Value51.8 M55.9 M
Tangible Asset Value36 M29.5 M

Technical Drivers

As of the 17th of June 2021, Armata Pharmaceuticals shows the mean deviation of 2.09, and Risk Adjusted Performance of (0.08). Armata Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We have collected data for nineteen technical drivers for Armata Pharmaceuticals, which can be compared to its rivals. Please confirm Armata Pharmaceuticals downside deviation, jensen alpha, as well as the relationship between the Jensen Alpha and downside variance to decide if Armata Pharmaceuticals is priced correctly, providing market reflects its regular price of 4.24 per share. Given that Armata Pharmaceuticals has jensen alpha of (0.34), we suggest you to validate Armata Pharmaceuticals's prevailing market performance to make sure the company can sustain itself at a future point.

Armata Pharmaceuticals Price Movement Analysis

The output start index for this execution was fourty-nine with a total number of output elements of twelve. The Exponential Moving Average is calculated by weighting recent values of Armata Pharmaceuticals more heavily than older values. View also all equity analysis or get more info about exponential moving average overlap studies indicator.

Armata Pharmaceuticals Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Armata Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Armata Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Armata Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Armata Pharmaceuticals Predictive Daily Indicators

Armata Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Armata Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Armata Pharmaceuticals Forecast Models

Armata Pharmaceuticals time-series forecasting models is one of many Armata Pharmaceuticals' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Armata Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Armata Pharmaceuticals Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Armata Pharmaceuticals stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Armata shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Armata Pharmaceuticals. By using and applying Armata Stock analysis, traders can create a robust methodology for identifying Armata entry and exit points for their positions.
Last ReportedProjected for 2021
EBITDA Margin(22.35) (22.94) 
Gross Margin 0.90  0.89 
Profit Margin(24.26) (26.17) 
Armata Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for the treatment of antibiotic-resistant infections worldwide. It has a partnership agreement with Merck Co. for developing proprietary synthetic phage candidates to target undisclosed infectious disease agents. Armata Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NYSEMKT Exchange. It employs 59 people.

Current Armata Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Armata analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Armata analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
7.75Strong Buy4Odds
Armata Pharmaceuticals current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Armata analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Armata stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Armata Pharmaceuticals, talking to its executives and customers, or listening to Armata conference calls.
Armata Analyst Advice Details

Armata Stock Analysis Indicators

Armata Pharmaceuticals stock analysis indicators help investors evaluate how Armata Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Armata Pharmaceuticals shares will generate the highest return on investment. By understating and applying Armata Pharmaceuticals stock analysis, traders can identify Armata Pharmaceuticals position entry and exit signals to maximize returns.
Quick Ratio1.52
Fifty Two Week Low2.5600
Shares Short Prior Month53.88k
Average Daily Volume Last 10 Day5.84k
Average Daily Volume In Three Month14.4k
Shares Percent Shares Out0.19%
Short Percent Of Float0.19%
Forward Price Earnings-4.09
Float Shares9.28M
Fifty Two Week High10.4800
Enterprise Value To Ebitda-5.17
Fifty Day Average4.1374
Two Hundred Day Average4.2855
Enterprise Value To Revenue128.50
Please continue to Trending Equities. Note that the Armata Pharmaceuticals information on this page should be used as a complementary analysis to other Armata Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for Armata Pharmaceuticals Stock analysis

When running Armata Pharmaceuticals stock analysis, check to measure Armata Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Armata Pharmaceuticals is operating at the current time. Most of Armata Pharmaceuticals' stock examination focuses on studying past and present price action to predict the probability of Armata Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Armata Pharmaceuticals' price. Additionally, you may evaluate how the addition of Armata Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Equity Search
Search for activelly-traded equities including funds and ETFs from over 30 global markets
Go
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
The market value of Armata Pharmaceuticals is measured differently than its book value, which is the value of Armata that is recorded on the company's balance sheet. Investors also form their own opinion of Armata Pharmaceuticals stock's value that differs from its market value or its book value, called intrinsic value, which is Armata Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Armata Pharmaceuticals' market value can be influenced by many factors that don't directly affect Armata Pharmaceuticals underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Armata Pharmaceuticals' stock value and its price as these two are different measures arrived at by different means. Investors typically determine Armata Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Armata Pharmaceuticals' stock price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.